Environmental Impact Acquisition Corp.

Environmental Impact Acquisition — GreenLight Biosciences — SPAC Merger (August 2021)

56 slides from Environmental Impact Acquisition's SPAC merger presentation, Aug 10, 2021

  1. Slide 1: What if we could make RNA accessible to everyone?

    What if we could make RNA accessible to everyone? Exhibit 99.2

  2. Slide 2: Disclaimer: Caution Regarding Forward Looking Statements

    Disclaimer Caution Regarding Forward Looking Statements Certain statements included in this Investor Presentation (“Presentation”) that are not historical facts are forward-looking statements for purposes of US law. Forward-looking statements generally are accompanied by words such as “believe,” “ma

  3. Slide 3: Disclaimer: Use of projections

    Disclaimer Use of projections This Presentation contains projected financial information with respect to GreenLight. Such projected financial information constitutes forward-looking information and is for illustrative purposes only. Financial projections should not be relied upon as necessarily bein

  4. Slide 4: Disclaimer: Trademarks and participants in the solicitation

    Disclaimer Trademarks All trademarks, service marks, and trade names of Environmental Impact Acquisition Corporation ("ENVI") or GreenLight or their respective affiliates used herein are trademarks, service marks, or registered trade names of Environmental Impact Acquisition Corporation ("ENVI") or

  5. Slide 5: Partner with a high-growth, market leading business

    Partner with a high-growth, market leading business, propelled by a large & growing market opportunity and a business model supporting critical Sustainability initiatives Revolutionary RNA technology offers truly differentiated solutions Addressing multiple billion-dollar Agricultural & Health marke

  6. Slide 6: GreenLight Bio & Environmental Impact - Shared mission to deliver global impact

    GreenLight Bio. & Environmental Impact - Shared mission to deliver global Impact Environmental Impact Acquisition Corp. Andrey J. Zarur, Ph.D CEO Susan Keefe, MBA CFO Dan Coyne CEO & President Marc Marano CFO GreenLight Biosciences ENVI is excited to be GreenLight’s aligned partner in its mission to

  7. Slide 7: GreenLight's vision and mission

    Create Solutions to major challenges facing humanity through the rigorous application of biological sciences Deliver Innovative RNA-based products for sustainable food production and human health, with our breakthrough synthetic biology platform Reward Our shareholders, employees, and stakeholders b

  8. Slide 8: GreenLight exists to bring RNA solutions to pressing challenges

    Greenlight exists to bring RNA solutions to solve some of the world’s most pressing challenges We will be 9 billion humans on earth by 2037, increasingly adopting a middle-class lifestyle. For survival of humanity and the planet, our diets must be less carbon-intense. We must stop clearing land and

  9. Slide 9: GreenLight's platform offers affordable RNA solutions to the world

    GreenLight’s pioneering platform offers affordable RNA solutions to the world We will enable affordable and globally scaled RNA applications in agriculture, and human health Higher Quality Agriculture-Grade Human-Grade In-vitro transcription Chemical synthesis Fermentation - not viable for RNA in ag

  10. Slide 10: Technology has removed barriers to RNA use in agriculture

    GreenLight technology has removed barriers to RNA use in agriculture by delivering Cost less than $1/g dsRNA Scale +1,000 L batch for multi-kg-scale dsRNA Opens a wide range of new and high-value applications for RNA in agriculture Agricultural RNA expertise enables new and newly accessible human he

  11. Slide 11: Our cell-free engine has overcome barriers for RNA

    Our cell-free engine has overcome development and commercialization barriers for RNA We remove hurdles to implementing and scaling RNA for human, plant, and animal health Identify Bioinformatics Tools such as machine learning and proprietary algorithms identify best gene target candidates to protect

  12. Slide 12: Collaborations and branded products enabled by our platform

    Enabled by our platform, we will pursue a mix of collaborations and branded products Cost-effective production can open up numerous categories of GreenLight products and collaborations GREDEC012E Food company partnerships Biomolecules, including sweeteners mRNA The instructions to make proteins dsRN

  13. Slide 13: Nine projected product launches through 2026

    Launch Launch Launch Launch Launch Launch Launch 6 more agricultural programs planned for 2027 and beyond 2021 2022 2023 2024 2025 2026 Colorado Potato Beetle Varroa Mite Botrytis Diamondback Moth Fusarium Powdery Mildew Two Spotted Spider Mite Covid Vaccine Seasonal Flu Supra-seasonal Flu Antibody

  14. Slide 14: Our Team

    Our Team Exceptional management team with diverse public company expertise and proven track record of success Andrey J. Zarur Ph.D CEO Charu Manocha MBA CPO Susan Keefe MBA CFO Thomas Crampton SVP & Head Corporate Affairs Carole Cobb MBA COO David Kennedy General Counsel Marta Ortega-Valle MBA CBO H

  15. Slide 15: Plant and animal health platforms

    Plant and animal health platforms: Insecticides, fungicides and acaricides

  16. Slide 16: First foliar RNA product highly competitive with premium solutions

    Price and performance of first-ever foliar RNA product highly competitive with other premium solutions The active ingredients in many conventional pesticides for Colorado Potato Beetle—and many for other pests—have a use rate 50x that of GreenLight and face increasing resistance by pests. Environmen

  17. Slide 17: Agricultural program pipeline and TAM

    Program Collaborator Discovery & lab studies Greenhouse trials Confirmatory trials POC field trials Regulatory submission Expected launch year TAM Colorado Potato Beetle 2022 $350M Varroa Mite 2024 $290M Botrytis 2025 $1.2B Diamondback Moth 2025 $890M Fusarium * 2025 $950M Powdery Mildew * 2025 $1.4

  18. Slide 18: Colorado Potato Beetle program

    Colorado Potato Beetles decimate fields of potatoes, eggplants, and bell peppers Untreated, 30 days 4 g of GreenLight RNA per acre Biodiversity-supporting solution to >$500M problem, from discovery to EPA submission in just four years Meets farmers’ buying criteria Equivalent efficacy to existing ch

  19. Slide 19: Farmers use standard application methods

    While farmers benefit from effective new tool, they use standard application methods Mixed with water and sprayed using standard agricultural practice over crops, the dsRNA is used at a rate of a few grams per acre. This is less than one-tenth the rate at which conventional industrial chemicals are

  20. Slide 20: Honeybee colony devastation threatens crops and food supply

    The 3 million commercial honeybee colonies in the United States are used to pollinate more than 100 crops annually that are worth an estimated $15 billion. Some crops, such as almonds, are almost entirely dependent on pollination. The single greatest threat to honeybees, Varroa destructor mite, has

  21. Slide 21: Saving honeybees: rapid roadmap to commercialization

    Saving honeybees: Rapid roadmap to commercialization December 10, 2020 GreenLight acquires from Bayer Input materials and formulation development dsRNA production and packaging validation GreenLight field trials in beehives Manufacture process and formulation locked Regulatory studies and registrati

  22. Slide 22: Human health applications: vaccines, therapies, antibodies

    Human health applications: Vaccines, therapies, antibodies Solutions for pandemics and more equitable access to novel therapies for grave diseases

  23. Slide 23: Human health pipeline focused on large markets

    Application Target Collaborator Early Pre-clinical Pre-clinical Toxicity Clinical Development Phase 1 | Phase 2 | Phase 3 Anticipated Clinical Development Start Date Vaccine COVID-19 updated for VoC H1 2022 Vaccine Seasonal influenza H2 2022 Gene Therapy Sickle Cell Disease gene TBD Antibody Therapy

  24. Slide 24: Vaccine candidate immune response comparison

    Company Mouse Neutralizing Ab Titer CD4 Response CD8 Response ~130,000 at 5µg dose Assay : Clinical Isolate Th1-bias 1.5 – 3.5% of CD4 T cells producing cytokines Very little Th2 cytokines by ELISA 5-12.5% of CD8 T cells responding to restimulation by flow cytometry ~300 at 5µg dose Assay : Pseudovi

  25. Slide 25: GreenLight's Covid-19 vaccine candidate

    GreenLight’s Covid-19 vaccine candidate All doses of GreenLight vaccine protected hamsters against weight loss following intranasal viral challenge Our GreenLight mRNA vaccine candidate induced high levels of binding and neutralizing antibodies at all doses tested Hamster body weight change on virus

  26. Slide 26: mRNA influenza vaccines in development

    Company Agent Name Description Stage of Development GLB-flu-xx Seasonal influenza Preclinical Phase 1 projected to begin 2H 2022 BNT-161 Seasonal influenza Preclinical Phase 1 to begin 2H 2021 mRNA-1010 mRNA-1020 mRNA-1030 mRNA-1440 Seasonal influenza Seasonal influenza Seasonal influenza Avian infl

  27. Slide 27: Promising GreenLight influenza vaccine candidate

    Promising GreenLight influenza vaccine candidate High levels of antibody production and protection against viral challenge Our vaccine candidates protect all mice from lethal influenza virus challenge Percent Survival Survival post-challenge with virus GLB quadrivalent candidate GLB HA+NA candidate

  28. Slide 28: Local production vision for Africa, Asia, and Latin America

    Our vision is to enable the Africa, Asia, and Latin America regions to meet local demand through local production. A global mRNA vaccine manufacturing network could dramatically increase vaccine supplies, eliminate vaccine nationalism, respond quickly to variants, and offer non-pandemic RNA manufact

  29. Slide 29: Gene therapy architecture for sickle cell disease

    Ribosome Cell Nucleus Target Target cell RNA-encoded instructions Target specific vehicle Proprietary approach for integration of wild-type beta-globin gene Can edit dividing and nondividing cells Do not require viral vectors Achieves long-lasting effect Are delivered direct to the patient Can be ma

  30. Slide 30: Manufacturing operations

    MANUFACTURING OPERATIONS Inside GreenLight’s production site for dsRNA

  31. Slide 31: Commercial plant for agricultural RNA began operation in Q1 2021

    GreenLight’s commercial plant for agricultural RNA began operation in Q1 2021 Rochester NY-based RNA production facility currently outfitted for 500 kg output per year

  32. Slide 32: Installed commercial capacity ready for expansion

    Installed commercial capacity of 500 kg per year, ready for expansion to 1,000 kg per year Rochester site infrastructure supports further expansion up to 100 metric tons per year

  33. Slide 33: Dynamic workforce in place; scale-up expertise and next steps

    Dynamic workforce in place, with ready access to additional skilled labor Located in the biotech-centric Eastman Business Park, home to 100+ innovative companies Scale-up expertise and next steps

  34. Slide 34: IP and collaborators

    tors i | | IP and collabora - ; - NU ~~

  35. Slide 35: Extensive and rapidly expanding IP portfolio

    Extensive and rapidly expanding IP portfolio 145+ patents and 165+ applications RNA Platform Foundational U.S. Patents 2 1 Foundational Japan Patent 61 Foundational Apps 10 Improvement Apps Process Control and Compound Production 53 Patents 9 Applications Human Health mRNA Platform App; RNA Gene The

  36. Slide 36: Our partners and collaborators

    Our partners and collaborators Life Sciences Advisors Dr. Drew Weissman Univ of Pennsylvania Luc Debruyne Former President GSK Global Vaccines Dr. Mark Dybul Former Exec Dir Global Fund Dr. Ted Ashburn Pres and CEO Oncorus Robert S. Langer MIT, Institute Professor Publicly-disclosed Collaborations M

  37. Slide 37: Opportunity Overview

    Opportunity Overview

  38. Slide 38: Plant health revenue - business plan

    Plant health revenue – business plan ($ in millions) $489.3 Products in market 0 0 1 2 7 8 8 GLB Product Revenue R&D Collab. Revenue Platform Mfg. Revenue $0.0 $0.6 $5.2 $18.9 $119.7 $320.7 Target gross margin of 75-90%1 for 2025 and beyond 1. Target gross margin is for products GreenLight distribut

  39. Slide 39: Human health revenue - business plan

    Human health revenue – business plan ($ in millions) Human health revenues largely expected in the form of royalties 1. 2021 Revenue reflects grant revenue $40.0 $181.1 $211.6 $729.5 $802.1 $749.2 $1.51

  40. Slide 40: Projected corporate financial metrics 2021-2025

    Projected corporate financial metrics 2021-2025 ($ in millions) 2021E 2022E 2023E 2024E 2025E Revenue1 $2 $41 $186 $231 $849 EBITDA1 ($114) ($190) ($11) ($23) $235 Capital Expenditures $14 $71 $52 $104 $32 Working Capital Investment $0 $69 $64 $61 $51 Non-GAAP financials based on management estimate

  41. Slide 41: Transaction summary and pro forma equity ownership

    ($ in millions except per share data) Share Price $10.00 Pro Forma Shares Outstanding (1) 156.4 Equity Value $1,564 Less: Net Cash from Transaction $282 Less: Existing Net Cash on Balance Sheet (2) $52 Implied Enterprise Value $1,230 Transaction Summary & Pro Forma Equity Ownership Pro Forma Valuati

  42. Slide 42: Anticipated use of proceeds

    Anticipated use of proceeds $282M (Estimated Cash in Trust and PIPE Proceeds) Launch pipeline of pest-protection products and first animal health product into market Expand into other biological molecules (microbials, peptides, etc.) and applications Corporate Development / General Corporate Build m

  43. Slide 43: GreenLight peer benchmarking

    GreenLight peer benchmarking Source: Company filings and FactSet as of 8/6/21. Ginkgo 2021E EV / sales reflects 2024E revenues, and 2022E EV / sales reflects 2025E revenues based on investor presentation. Moderna 2021 EV / sales reflects EV / LTM revenues. BioNTech 2021 EV / sales reflects EV / LTM

  44. Slide 44: GreenLight has significant upside potential

    Ag & Food Production Healthcare ($ in millions) ($ in millions) Healthcare EV / 2024E revenue multiple: 8.4x Ag & Food EV / 2026E revenue multiple: 14.4x Healthcare implied enterprise value: $1,781 Ag & Food implied enterprise value: $4,622 $6,403 GreenLight has significant upside potential

  45. Slide 45: Summary of valuation approach

    Applies a range of 8.0x – 8.8x to GreenLight’s 2024E Human Health revenue of $212m and 13.7x – 15.1x to its 2026E Plant Health revenue of $321m to arrive at an implied future enterprise value Multiple range based off range of Healthcare EV/CY 2024E revenue trading multiple of 8.4x +/- 5% and Ag & Fo

  46. Slide 46: Why invest in us?

    Why invest in us? 1 Cutting edge, proven technology to democratize RNA, making it available to solve problems in the world’s most important markets: Agriculture, Food Production and Health Synthetic biology platform capable of producing RNA at scale, underscoring power of manufacturing at scale with

  47. Slide 47: Corporate contacts page

    Corporate contacts page: Thomas Crampton GreenLight Biosciences SVP and Head of Corporate Affairs 200 Boston Ave Medford, Massachusetts 02155

  48. Slide 48: Appendix: Additional Human Health details

    Appendix: Additional Human Health details

  49. Slide 49: GreenLight mRNA Human Health commercial process today

    Nucleotides GreenLight mRNA Human Health commercial process today Proprietary GreenLight approach consolidates key processes under single roof Modular, scalable and with reduced logistical complexity Proprietary enzyme and fermentation processes generate required essential materials, including T7 an

  50. Slide 50: Next generation mRNA manufacturing process

    5 Kinases Polyphosphate Capping Nucleotides Purification Formulation Cell-free production of mRNA Fermentation DNA Template RNA polymerase Microbial strain Purification Fermentation Microbial strain Linearization Purification Microbial strain Fill and Finish CMP à CTP UMP à UTP GMP à GTP AMP à ATP N

  51. Slide 51: GreenLight Covid vaccine has considerable potential

    GreenLight Covid vaccine has considerable potential Endemic Covid expected to drive global vaccine demand to ~$20B in 2027 Covid-19 Challenge Our Proposed Solution Only 21 doses for every 100 people have been administered worldwide Periodic booster dose may be necessary GLB-Covid-19 variant updated

  52. Slide 52: GreenLight influenza vaccine tackles significant current problems

    GreenLight influenza vaccine tackles significant current problems Need for greater efficacy and shorter cycle times for seasonal vaccine updates ~$3.3B market Influenza Challenge Our Proposed Solution GLB-Covid-19 variant updated vaccine candidates GLB proprietary RNA vaccine manufacturing platform

  53. Slide 53: Appendix: Summary Risk Factors

    Appendix: Summary Risk Factors

  54. Slide 54: Summary Risk Factors

    Summary Risk Factors Risks relating to the proposed business combination: GreenLight has a limited operating history, which makes it difficult to evaluate our current business and prospects and increases the risk of investment. We have a history of net losses, and we may not achieve or maintain prof

  55. Slide 55: Summary Risk Factors (cont'd)

    Summary Risk Factors Risks relating to the proposed business combination (cont’d): The unpredictability of the spread and treatment of the SARS-CoV-2 virus and its variants could materially harm our business prospects. Intellectual property rights including patents and patent applications involve hi

  56. Slide 56: Summary Risk Factors (cont'd)

    Summary Risk Factors Risks relating to the proposed business combination (cont’d): The consummation of the merger is subject to a number of conditions and if those conditions are not satisfied or waived, the merger agreement may be terminated in accordance with its terms and the merger may not be co

GreenLight Biosciences — SPAC Merger (August 2021) on 6ix